2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.

Key Points Vertex Pharmaceuticals is the leader in the cystic fibrosis market and has the intellectual property to maintain this dominance. The company has expanded into additional treatment areas and is awaiting a regulatory decision for another potential new product in the coming weeks. 10 stocks we like better than Vertex Pharmaceuticals › Vertex Pharmaceuticals (NASDAQ: VRTX) has been a clear winner for investors over time. Earnings and stock performance have progressed steadily thanks to the company's dominance in the cystic fibrosis (CF) treatment market and its success in broadening its presence into other areas.